Financial Data and Key Metrics Changes - The company's third quarter revenues were approximately $382 million, representing a decrease of 0.4% on an organic basis, impacted by a $7 million return reserve increase due to the Boston facility issues [81][91] - Adjusted gross margin for the quarter was 64.6%, down 210 basis points compared to the previous year, primarily driven by the Boston impact [94] - Adjusted earnings per share were $0.76, down $0.10 compared to the prior year, reflecting the Boston recall and planned growth investments [94][112] Business Line Data and Key Metrics Changes - In the CSS segment, reported revenues were $268 million, an increase of 7.4% on both reported and organic bases, exceeding growth expectations [95] - The Tissue Technologies segment saw a decline of 15.6% on a reported basis, but excluding Boston, organic growth was 6.7%, driven by strong demand in other product lines [100] - International sales in the CSS segment grew low-double-digits, particularly in China, Australia, and Canada, indicating strong demand and effective regional strategies [99] Market Data and Key Metrics Changes - The company experienced strong international growth at nearly 12%, with significant contributions from various regions [82] - The Boston facility's impact was significant, with an estimated total impact of $67 million on topline revenue for 2023, affecting both sales and earnings [126] - The company anticipates a return to market for products from the Boston facility by mid-to-late second quarter of 2024, which is expected to stabilize revenue streams [75][116] Company Strategy and Development Direction - The company is focused on remediation efforts at the Boston facility, with plans for external audits and a return to market for key products like SurgiMend and PriMatrix [75][116] - There is an emphasis on international growth strategies, including geographic expansions and new product registrations, to leverage existing technologies [86] - The company is exploring M&A opportunities, particularly in the Codman Specialty Surgical segment, while prioritizing capital allocation towards long-term growth initiatives [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the remediation progress at the Boston facility and the expected timelines for product re-launches, indicating a commitment to restoring customer trust [75][116] - The company acknowledged challenges due to the Boston recall but highlighted strong underlying growth performance across other segments, with organic growth of 7.1% excluding Boston [93][116] - Future guidance indicates a moderate decline in gross margins for 2023, with expectations for recovery as operational efficiencies improve [112] Other Important Information - The company has strengthened its executive leadership by appointing a new Chief Human Resources Officer to enhance organizational capabilities [88] - The balance sheet remains strong, with ample liquidity to support both short and long-term plans, including a total liquidity of $1.5 billion [104] - The company issued its second annual ESG report, detailing progress in sustainability and corporate responsibility initiatives [89] Q&A Session Summary Question: What was the reason for the $7 million increase in return provisions related to the Boston facility? - The increase was due to better visibility into customer inventory and returnable products after working closely with customers post-recall, leading to a more accurate assessment of returns [126] Question: How much market share does the company expect to recapture following the re-launch in mid-2024? - The company estimates it will return to about 100% of its business within 12 months post-relaunch, driven by strong customer relationships and product merits [131] Question: What percentage of sales comes from China, and how might increased anti-corruption issues affect access to hospitals? - Sales from China account for about 5% to 6% of total sales, primarily in the neurosurgery portfolio, and the impact from anti-corruption issues is not expected to be material [133]

Third Quarter 2023 Net Debt Reconciliation Revenue $1.541B-$1.547B | --- | --- | --- | |--------------|-------------------------------------------------------|---------------------| | Neurosurgery | Q3 2023 Growth and Performance Drivers2 \nInstruments | International | | 8.0% | 5.0% | Double-Digit growth | Private Label 22.9% Wound Reconstruction 77.1% IART Q3 2023 Earnings Presentation Note: Organic growth, adj. gross margin, adj. EBITDA margin and adj. EPS are non-GAAP financial measures. $193.1 IART Q3 ...

Non-GAAP Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, adjusted gross profit, adjusted gross margin, free cash flow and adjusted free cash flow conversion. Organic revenues consist of total revenues excluding the effects of currency exchange rates, revenues from current-period acquisitions and pro ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE OR O ...

For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NO. 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE OR ...

Q1 2023 EARNINGS PRESENTATION APRIL 26, 2023 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like "will," "believe," "may," "could," "would," ...

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q1 2023 Earnings Conference Call April 26, 2023 8:30 AM ET Company Participants Chris Ward – Senior Director-Investor Relations Jan De Witte – President and Chief Executive Officer Mathieu Aussermeier – Vice President-FP&A, Investor Relations and Treasurer Conference Call Participants Vik Chopra – Wells Fargo Ryan Zimmerman – BTIG Craig Bijou – Bank of America Eric Fleming – Raymond James Rohan Patel – JPMorgan Chase Drew Ranieri – Morgan Stanley Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NO. 000-26224 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 51-0317849 (STATE OR OTHER ...

Neurosurgery market recovery offset by CereLink recall and supply challenges Revenues Q4'22 Q4'21 Growth 1 Q4'21 reported revenue includes TWC 2Q4'22 excludes $0.5M of acquired SIA revenues and ($1.1M) in foreign exchange; 3Percentages based on organic revenue, Commentary represents organic performance, Comparisons are to prior year Adj. Gross Profit Adj. EBITDA Adj. EPS Adj. Gross Profit Adj. EBITDA Adj. EPS 0 0.2 0.4 0.6 0.8 1 1.2 $1,043.5 $1,046.4 -20 -15 -10 -5 0 5 10 15 20 FY'21 FY'22 325 335 345 355 3 ...

Integra LifeSciences Holdings Corporation. (NASDAQ:IART) Q3 2022 Earnings Conference Call October 26, 2022 8:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Jan De Witte - President & Chief Executive Officer Carrie Anderson - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG David Turkaly - JPM Vik Chopra - Wells Fargo Matthew Taylor - Jefferies Steve Lichtman - Oppenheimer Drew Ranieri - Morgan Stanley Richard Newitter - Truist Operator Hello and welc ...